pharmaphorum

AUGUST 5, 2021

Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. PPIs are an integral part of the physiology of living organisms, as complexes which control biological pathways mediated by proteins. These regions are critical for optimal interactions between proteins.

Protein 126

Protein Gene Bioassay DNA 126

Pharmaceutical Technology

JUNE 23, 2022

Researchers at the University of New Hampshire (UNH) have found that a repurposed drug, CCG-50014, could hinder the activity of a key enzyme of the SARS-CoV-2 virus, which causes Covid-19. Utilising a currently available drug compound in a new way is called drug repurposing.

Drugs 130

Drugs Protein Genome Genomics 130

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Pharmaceutical Technology

JANUARY 25, 2023

French biopharmaceutical firm Poxel has received orphan drug designation (ODD) from the European Commission (EC) for its molecules PXL770 and PXL065 to treat adrenoleukodystrophy (ALD). PXL770 is a new, first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK).

Drugs 130

Drugs Genome Genomics Medicine 130

Drug Discovery World

AUGUST 21, 2023

SBIR fast-track grant from the NIH to apply its proprietary Multiplexed Assays for the Rational Modulation Of Transcription Factors (MARMOT) platform to their deep learning AI model and accelerate the development of transcription factor drugs. Talus Bio was also awarded a $2.0M The post $4.3

Drugs 98

Drugs Gene Expression Protein Gene 98

Drug Discovery World

OCTOBER 26, 2023

The technologies cover the whole range of biomolecules from genes to protein to metabolites. While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods.

Drugs 52

Drugs Protein Genome Genomics 52

Drug Discovery World

OCTOBER 2, 2023

X-Chem and the Structural Genomics Consortium (SGC) have entered a collaboration aimed at creating new chemical tools to study human proteins. Under the agreement, X-Chem will use its DEL platform to create datasets for proteins chosen and supplied by the SGC, which will be posted to a public portal to be used for model building.

Genome 52

Genome Genomics Protein DNA 52

pharmaphorum

SEPTEMBER 16, 2022

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome.

Development 135

Development Research Drugs Clinical Trials 135

Pharmaceutical Technology

FEBRUARY 23, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: In-silico drug discovery. Codexis, a protein engineering company, is the leading patent filer.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Scienmag

NOVEMBER 20, 2020

It contains the information for the production of 27 proteins. This is not much compared to the possible 40,000 kinds of protein that a […].

Genome 70

Genome Genomics RNA Protein 70

Drug Discovery World

JANUARY 26, 2023

This is the latest episode of the free narrated DDW podcast, “CRO’s and targeted protein degradation offer an exciting future”. They are called “ CROs: Drug discovery expertise on hand ” and “ Why the emergence of targeted protein degradation is so exciting ”.

Protein 52

Protein Drugs Research Marketing 52

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. T790M loss has been linked to earlier resistance and poorer survival in other cohorts.

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

FEBRUARY 22, 2024

Following the first regulatory approval of a CRISPR-based drug in late 2023, over ten years since the CRISPR-Cas9 system was elucidated, there is considerable optimism about the future potential for gene editing technologies. appeared first on Drug Discovery World (DDW).

Gene Editing 52

Gene Editing Gene Genome Genomics 52

pharmaphorum

MAY 12, 2022

Bristol-Myers Squibb’s Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause them to be broken down.

Protein 52

Protein Genome Genomics Drugs 52

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives. The researchers discovered that Ebola virus polymerase hijacks a cellular protein called GSPT1.

Protein 52

Protein Genome Genomics Research 52

Drug Discovery World

APRIL 19, 2023

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Credit: Julia Sero/ICR The post Immuno-oncology collaboration to develop new type of cancer drug appeared first on Drug Discovery World (DDW).

DNA 98

DNA Development Drugs Genome 98

Drug Discovery World

MARCH 7, 2023

DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. By 2025, it’s estimated that Qatar’s drug market will reach a compound annual growth rate (CAGR) of 3.9%

Biobanking 52

Biobanking Drugs Genome Genomics 52

Drug Discovery World

NOVEMBER 10, 2023

With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. The post This week in drug discovery (6-10 November) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Genome Genomics Research 52

Drug Discovery World

FEBRUARY 20, 2024

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

The Pharma Data

DECEMBER 17, 2020

Food and Drug Administration (FDA) had several approvals this week. Food and Drug Administration (FDA) has approved belimumab (Benlysta®), the first-ever treatment for adults with lupus nephritis (LN) who are currently receiving standard therapy. Read on to see what the regulatory agency gave the go-ahead to. GlaxoSmithKline.

FDA Approval 52

FDA Approval Genome Genomics Production 52

Drug Discovery World

MAY 25, 2023

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. The post The latest drug discovery product launches appeared first on Drug Discovery World (DDW).

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

JULY 12, 2022

The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, restoring sensory and motor function after spinal injury.? . Co-author, Dr Richard Tuxworth?from References . 1: Ahmed Z, Tuxworth RI.

DNA 52

DNA Drugs Genome Genomics 52

pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.

Genome 64

Genome Genomics DNA Drugs 64

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .

RNA 52

RNA Genetic Disease Drugs Protein 52

Drug Discovery World

NOVEMBER 8, 2022

Mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines. . The findings could lead to modified versions of existing drugs or new drugs that account for the current mutations to increase their effectiveness. .

Drugs 52

Drugs DNA Vaccination Vaccine 52

Drug Discovery World

DECEMBER 12, 2022

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month. . Everyone enjoys a good news story and the drug discovery and development sector is no exception. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

DNA 52

DNA Immune Response Genome Genomics 52

Drug Discovery World

NOVEMBER 14, 2023

A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. Since the mutation only affects a single gene, it makes it a prime candidate for genome editing treatments.

In-Vivo 52

In-Vivo Gene Editing Gene Genome 52

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

SEPTEMBER 1, 2023

In the new study, led by scientists at The Institute of Cancer Research and published in Nature Communications , researchers identify a new cellular role of a protein called EXD2 nuclease and, importantly, its role in the so-called ALT (alternative lengthening of telomeres) pathway.

Drugs 59

Drugs Protein Research DNA 59

The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Protein 40

Protein Development Genome Genomics 40

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR!” billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

JUNE 5, 2023

Meet the biotech: Enhanc3D Genomics Enhanc3D Genomics was spun out from the laboratories of Dr Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organisation of the genome at the Babraham Institute in Cambridge, UK.

Genome 52

Genome Genomics Life Science Genetics 52

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. The post Conversations from ESMO Targeted Anticancer Therapies Congress 2024 appeared first on Drug Discovery World (DDW). We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64